4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

first_img 4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug Biotech Ruby Wallau for STAT What’s included? The annual Alzheimer’s research meeting known as CTAD was supposed to be a snoozefest this year. That all changed six weeks ago, when Biogen stunned the medical world by bringing an Alzheimer’s drug back from the dead — and vowed to make a detailed scientific case for the decision at the gathering this week.On Thursday morning, Biogen will give that highly anticipated presentation — livestreamed here — detailing data from two late-stage clinical trials of its drug, known as aducanumab. It will be the highlight of CTAD, short for Clinical Trials on Alzheimer’s Disease. Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED GET STARTED By Rebecca Robbins Dec. 4, 2019 Reprints Log In | Learn More What is it? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Tags agingbiotechnologyBostondementiaSTAT+last_img

Leave a Reply

Your email address will not be published. Required fields are marked *

*
*